cagrisema glp 1 obesity drug: what the phase 3 data shows GLP-1 based medicines for emerging

However, studies indicate that metformin for adolescents may increase the incidence of mild to severe gastrointestinal side effects, such as nausea, vomiting, diarrhea, and flatulence

Dopamine and reward-pathway research In addition, researchers use bremelanotide to study how melanocortin receptors interact with dopamine, GABA, oxytocin, and hypothalamic circuits involved in sexual motivation

On April 15, 2026 , the FDA removed DSIP (Emideltide) from Category 2 after the original nominations were withdrawn

Instead, we saw consistent signals of benefit across multiple measures. The medications may be particularly beneficial for patients with Type 1 diabetes who also have obesity or metabolic syndrome